My oncologist sent out an email to patients recommending that we contact our US Senators and Representatives to OPPOSE this change. Are you hearing the same from your providers?
Press release from the US Oncology Network:
apnews.com/press-release/pr...
Federal Register :: Most Favored Nation:
federalregister.gov/documen...
Text from my oncology office:
MFN is bad for patients. If passed, this rule will likely cause severe disruptions in access to important medications. The Center for Medicare & Medicaid Services (CMS) admits outright that the policy will likely hurt patients, stating that, “beneficiaries may experience access to care impacts by…having to travel to seek care from an excluded provider, receiving an alternative therapy that may have lower efficacy or greater risks, or postponing or forgoing treatment.”
In addition, CMS also commented that in 2021 9 percent of Medicare beneficiaries are projected to forgo access to treatment because of the MFN rule. That number increases to 19 percent Medicare beneficiaries in 2023. Further, CMS predicts in 2023 19 percent of Medicare beneficiaries will no longer have access to life saving cancer treatment because of the MFN rule.
MFN is bad for healthcare providers. 36 of the 50covered drugs under MFN are used in oncology and hematology. While we understand and agree that action is needed to address the rising cost of prescription drugs, including cancer treatments, the MFN is a rushed policy that is likely to have significant unintended and disastrous consequences on America’s seniors.
The American Hospital Association stated, “It is alarming that the Administration has issued this operationally burdensome rule after over two years, in the middle of a pandemic with cases at record levels, and with less than six weeks’ notice before the model begins.”